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Abstract
Objective: To assess the prevalence of  ESBL producing and carbapenem resistant Klebsiella pneumoniae isolated from in-come 
and out-come patients at Sahloul-university hospital.
Methods: A retrospective study over a 3 years period (January 2012 and December 2014) focused on 2160 strains of  Klebsiella 
pneumoniae. Statistical analysis was carried out using SPSS program. ESBL detection was performed using a double disc diffusion 
method and carbapenemase detection was realized by Rosco-Disk kit.
Results: A total of  2160 Klebsiella pneumoniae strains were isolated during the period of  the study, 26.2% (n=566) were ESBL-pro-
ducers and 15.8% (n=342) showed resistance to carbapenem. The wards most affected by these strains were basically urology 
and intensive care units. Eighty four percent of  studied strains (203/241) were resistant to temocillin, which correlate with the 
production of  a class D (OXA-48-like) carbapenemase and 7% (17/241) showed sensitivity to EDTA and dipicolinic acid, which 
indicate the production of  metallo-enzyme. The rate of  resistance to colistin remains low. 
Conclusion: Resistance of  Enterobacteriaceae, including K. pneumoniae, to third generation cephalosporins (3rd GC) and carbapen-
em through the mechanism of  ESBL and carbapenemases production is becoming increasingly worrying. This suggests a more 
rational use of  antibiotics, as well as the rigorous application of  hygiene measurement.
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Hospital infections have become a growing healthcare 
challenge in recent decades and serious concerns have 
been expressed over the rise in antimicrobial resistance 
among pathogens causing hospital-acquired infections. 
The progression of  bacterial resistances to antibiotics 
confronts clinicians with infections that are difficult to 
treat and poses a public health problem.
In view of  emergence of  ESBL and AmpC-producing 
bacteria, carbapenems are the β-lactam group of  drugs 
that are often used as antibiotics of  last resort and have 
shown their stability for treating infection due to multi-
drug-resistant bacteria1. As consequence of  over-use of  
this treatment, the situation has changed with the emer-
gence of  carbapenem- resistant bacteria both in fermen-
ters Gram-negative bacilli (Enterobacteriaceae) and non-fer-
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menters bacteria (Acinetobacter baumannii and Pseudomonas 
aeruginosa)2. Gram-negative bacteria play a significant role 
and have the strongest impact on the development and 
the emergence of  antimicrobial resistance. 
Resistance to carbapenems is mediated by two principal 
mechanisms: (i) production of  ESBL and/or AmpC en-
zymes with non-significant carbapenemase activity com-
bined with loss of  porin or up-regulation of  efflux pump 
(ii) secretion of  carbapenem-hydrolyzing β-lactamases.
The risk of  spreading of  Enterobacteriaceae producing 
carbapenemases is a major public health issue, as these 
enzymes restrict treatment options and are often asso-
ciated with other mechanisms, conferring multi-resis-
tance strains3. Invasive infections with these organisms 
have been associated with high rates of  morbidity and 
mortality4. Despite the recommendations concerning 
the rational use of  antibiotics and the strengthening of  
hygiene procedures to limit the emergence of  multidrug 
resistant bacteria, the number of  epidemics due to car-
bapenemase-producing bacteria has been increasing in 
several countries throughout the world. Tunisia was not 
spared were carbapenemases producing Enterobacteriaceae 
has increased in a spectacular way.  The first report of  
carbapenemases bacterial production in Tunisia was in 
20105. The most described carbapenemases can belong 
to clavulanic-acid inhibited β-lactamases (KPC), metal-
lo-β-lactamases (NDM) or expended spectrum oxacilli-
nases (OXA-48). 
The aim of  this study was to describe the general state of  
the evolution of  resistance in Enterobacteriaceae and espe-
cially in Klebsiella pneumoniae isolated in the laboratory of  
microbiology in Sahloul hospital and to phenotypically 
elucidate the mechanisms responsible for resistance to 
the molecules of  carbapenems.
Global methodology of  the undertaken survey
A retrospective investigation was carried out over a peri-
od of  three years from 01/01/2012 to 31/12/2014 in the 
laboratory of  microbiology in Sahloul hospital, a 629 beds 
university hospital with surgical vocation. The descriptive 
part of  this study concern epidemiology of  resistance to 
antibiotics in Enterobacteriaceae and statistical analysis was 
carried out using the SPSS software (version 20) and data 
from the laboratory. Phenotypic detection of  the mecha-
nisms responsible for carbapenem resistance was carried 
out on Klebsiella pneumoniae strains isolated from the vari-
ous samples taken from hospitalized patients and patients 
consulting in the external services of  the hospital (emer-
gencies, consultations urology, nephrology, gastrology).
Anti-microbial susceptibility testing was performed by 
classic method of  disk diffusion on Mueller–Hinton agar 
plates. This test was performed for all isolates. Differ-
ent classes of  antibiotics were tested including β-lactam 
and non β-lactam antibiotic containing disks (Bio-Rad, 
France). The antibiotics used were: ampicillin, piperacil-
lin, ticarcillin, ampicillin-clavulanic acid, piperacillin-tazo-
bactam, ticarcillin-clavulanic acid, cephalotin, cefuroxime, 
cefepime, cefoxitin, cefotaxime, ceftazidime, ertapenem, 
imipenem, aztreonam, gentamicin, amikacin, kanamycin, 
netilmicin, tobramycin, tetracyclin, ciprofloxacin, levo-
floxacin, ofloxacin, nalidixic acid, colistin, sulfonamides, 
trimethoprim and chloramphenicol. Results were inter-
preted according to the guidelines of  the European com-
mittee on Anti-microbial Susceptibility testing (EUCAST 
2015; www.eucast.org).
To detect ESBL producing strains, double disc synergy 
test was used: the picture of  synergy between the disc 
of  third generation cephalosporin antibiotic (ticarcillin) 
and other containing clavulanic acid (ampicillin-clavulan-
ic acid) confirm the presence of  ESBL enzyme. Pheno-
typic detection of  carbapenemases producing strains was 
carried out for ertapenem resistant strains using ROSCO 
KPC/MBL and OXA-48 Confirm Kit (ROSCO Diag-
nostica, Taastrup, Denmark) as a perform phenotypic 
test to elucidate the presence and the class of  carbapene-
mases. Principle of  this test was to compare diameter of  
resistance of  meropenem alone and in combination with 
different inhibitors: dipicolinic acid against metallo-β-lac-
tamases, aminophenylboronic acid against Ambler class 
A β-lactamase and cloxacillin against AmpC cephalospo-
rinase. Temocillin was used for presumptive detection of  
Ambler class D oxacillinases enzymes producers (table 1).
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Results and discussion
A- General features 
Enterobacteriaceae is a large family that includes several 
species which are the most commonly isolated between 
human pathogens in a bacteriological laboratory, in both 
community and hospital settings. They are responsible of  
many diseases such as urinary, respiratory and abdomi-
nal tract infections and septicemia6,7. Escherichia and Pro-
teus predominate in the intestinal commensal flora. They 
sometimes act asopportunistic pathogens. The Klebsiella, 
Enterobacter, Citrobacter, Serratia, Morganella and Providencia 
genera found in wastewater, soils and in small quantities in 
the gastrointestinal tract can cause serious infections due 
to their resistance to antibiotics, particularly in hospitals8.
          Table 1: Interpretation of disc ROSCO results 
 
  MRP+Cloxacilline MRP+PBA MRP+Dip.acid Temocillin 
Class A carbapenemases - + (≥5mm) - - 
Class B carbapenemases - - + (≥5mm) +/- 
Class D carbapenemases - - - + 
AmpC+porin loss + (≥5mm) +/- - - 
                             
                              MRP: Meropenem; PBA: Aminophenylboronic acid; Dip.acid: Dipicolinic acid; AmpC: Cephalosporinase 
          Table 1: Interpretation of disc ROSCO results 
 
  MRP+Cloxacilline MRP+PBA MRP+Dip.acid Temocillin 
Class A carbapenemases - + (≥5mm) - - 
Class B carbapenemases - - + (≥5mm) +/- 
Class D carbapenemases - - - + 
AmpC+porin loss + (≥5mm) +/- - - 
                             
                              MRP: Meropenem; PBA: Aminophenylboronic acid; Dip.acid: Dipicolinic acid; AmpC: Cephalosporinase 
At Sahloul hospital in Sousse, Enterobacteriaceae are also 
among the most isolated species in microbiological labo-
ratory. These bacteria are mainly responsible for urinary 
infections. It is known that urinary infections with Entero-
bacteriaceae are due to the migration of  these germs from 
the digestive tract to the urinary tree. The anatomical rea-
sons explain their greater frequency in the woman but 
all the causes of  stasis (lithiasis, compression, pregnancy) 
constitute factors favoring the infection.
During the period of  study, a total of  9054 strains of  En-
terobacteriaceae were isolated in the laboratory, Escherich-
ia coli is the most isolated species followed by Klebsiella 
pneumoniae both at community and nosocomial infections 
(Table 2).




2012 2013 2014   
Total 












Escherichia coli 940 503 1131 593 1066 686 4919 
Klebsiella 
pneumoniae 
370 301 465 325 421 278 2160 
Enterobacter cloacae 82 125 74 123 79 135 618 
Morganella morganii 31 28 22 32 18 42 173 
Klebsiella oxytoca 16 43 18 44 20 28 169 
Klebsiella spp 4 6 1 4 1 1 17 
Others species 71 193 200 204 131 199 998 
Total 1514 1199 1911 1325 1736 1369 9054 
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B-Klebsiella pneumoniae in Sahloul university hos-
pital-Tunisia
According to the high incrimination of  Klebsiella pneumoni-
ae in nosocomial and community-acquired infections and 
to the alarming and evolutionary profile of  resistance to 
antibiotics, our study was focused on the description of  
the epidemiology of  Klebsiella pneumoniae strains.
In our hospital, 2160 Klebsiella pneumoniae were selected 
during three years: 1250/2160 (43%) were isolated from 
patients hospitalized in different wards and 910/2160 
(57%) were isolated from external consultant patients. 
Klebsiella pneumoniae is a common pathogen that causes 
both community-acquired and hospital-acquired infec-
tions associated with high morbidity and mortality rates 9. 
Post-surgery and intensive care units present the wards 
where we observe most infections and resistant strains 
(table 3), followed by nephrology and urology which have 
also the most important number of  Klebsiella pneumoniae 
isolated strains both in terms of  internal and external 
consultation services (Figure 1, 2).
Ward 
 
                                                                                                                                                      Number of strains 
 
Figure 1: Distribution of Klebsiella pneumoniae in internal wards in the university hospital Sahloul, Sousse Tunisia (2012-2014) 
External consultation service 
                                                      




Figure 2: Distribution of Klebsiella pneumoniae in external consultation services 
(community-acquired strains) (2012-2014) 
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According to the type of  specimen, Klebsiella pneumoniae 
strains are essentially isolated from urine (71%), espe-
cially in women (892/1551 urine samples). Nevertheless, 
the frequency of  isolation in blood remains high (12%) 
(Figure 3). The most frequent infections sites with Kleb-
siella pneumoniae are the respiratory and urinary tracts. K. 
pneumoniae can cause infections in young and very old pa-
tients; however, they are most common in those whose 
immune system is compromised either through disease 
(alcoholism, diabetes) or therapy (antimetabolites) 9, 10. 
C- Antibiotic resistance in Klebsiella pneumoniae strains iso-
lated in the universityhospital Sahloul Tunisia (2012-2014)
 
Figure 3: Distribution of Klebsiella pneumoniaeaccording to nature of samples 
The advent of  antibiotic therapy in the 1940s led to rev-
olution of  medical field and to a significant reduction in 
mortality associated with infectious diseases. Unfortu-
nately, bacterial resistance to traditional antibiotics has 
rapidly constituted a major health problem on a global 
scale. The resistance to penicillin was described in the 
1950s, to the first-generation cephalosporins in the 1970s 
and to the third generation cephalosporins in the 1990s. 
In recent years, the frequency of  infections caused by 
resistant bacteria has increased both in hospitals and in 
community. Resistance can now be observed in almost all 
potentially pathogenic bacteria11. 
In regard to Klebsiella pneumoniae, this species belong 
to group 2 of  Enterobacteriaceae, which include species 
naturally resistant to amino and carboxypenicillins12. 
In our study, and based on the antibiogram profiles, 
38.6% (834/2160) of  studied strains presented the wild 
phenotype, meaning resistance to amino and carboxypen-
icillins. This specie is an important source of  transfer-
able antibiotic resistance and several hospital outbreaks 
of  infection are caused by multiresistant Klebsiella pneu-
moniae strains. Third generation cephalosporins such as 
cefotaxim, ceftriaxone and ceftazidime, are used as a very 
effective treatment against infections caused by Enterobac-
teriaceae. Their prescription is generally reserved for severe 
infections. Similarly, they are used with some success in 
nosocomial infections. The over use of  these molecules, 
led to the appearance of  resistant strains by the produc-
tion of  ESBL enzymes: 26.2% (566/2160) of  studied 
stains correspond to the phenotype of  ESBL producers 
Klebsiella pneumoniae. 
African Health Sciences Vol 19 Issue 2, June, 2019 2012



















Nephrology 1262 47 1317 71 1331 55 
Urology 3055 72 2862 53 2940 45 
Intensive care unit and 
Post-surgery 
1119 106 985 90 1110 73 
General surgery 3248 40 3316 38 3218 46 
Pediatric unit 1591 30 1748 39 2039 41 
Physical medicine 150 31 226 20 216 37 
Orthopedy 6073 15 5318 34 5318 20 
Internal medecine 599 8 588 18 523 22 
Medical intensive care 86 9 79 8 85 14 
Gastrology 898 5 894 10 925 10 
Cardiology 2793 6 2694 11 2471 8 
Neuro surgery 835 4 916 10 849 8 
Maxillo facial surgery 1712 0  1586 6 1589 6 
Other wards 8085 - 7100 - 5814 - 
Total of admission 31506 - 29629 - 28428 - 
In front of  the emergence of  β-lactamase and multire-
sistant strains to several families of  antibiotics, carbape-
nem was used as last-resort molecules for the treatment 
of  infections due to multidrug-resistant bacteria, as con-
sequence, carbapenem resistant strains were emerged. 
In our study, 15.8% (342/2160) of  studied strains cor-
respond to the phenotype of  carbapenemase producers 
strains. 
Besides ESBL and carbapenemases phenotypes, sever-
al other type of  resistance can be described in Klebsiella 
pneumoniae including high-level penicillinase-producing 
strains, hyper produced cephalosporinases, aminoglyco-
side and fluoroquinolone-resistant strains (table 4). 
Table 4: Distribution of resistance phenotypes during the studied period 
 
  
2012 2013 2014 Total  







Wild-type 254 (37,8%) 316 (40,0%) 264 (37,8%) 834 (38,6%)  Carbapenemase 119 (17,7%) 78 (10,0%) 145 (20,7%) 342 (15,8%)  ESBL 186 (27,8%) 231 (29,2%) 149 (21,3%) 566 (26,2%)  Others 112 (16,7%) 165 (20,8%) 141 (20,2%) 418 (19,3%)  Total 671 (100%) 790 (100%) 699 (100%) 2160 (100%)    
a-Resistance to cephalosporins
Cephalosporins are antibiotics belonging to the large fam-
ily of  β-lactams. These molecules had been developed in 
response to the increased prevalence of  β-lactamases like 
TEM-1 and SHV-113. The molecules which can be used in 
medicine are semisynthetic derivatives of  cephalosporin 
C; the first was cefalotin, discovered in 1962, belongs to 
the first-generation cephalosporins14. Other derivatives 
have been progressively discovered to the current range 
of  cephalosporins. Among the most used molecules in 
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therapeutics, we found cefuroxim and cefoxitin belongs 
to the second-generation cephalosporins, and cefotaxim 
belongs to third generation cephalosporins. The spectrum 
of  action of  successive generations of  cephalosporins is 
different. The first generation has a spectrum mostly ori-
ented towards Gram positive bacteria, the second has an 
intermediate spectrum and the third generation sees its 
spectra widen towards Gram negative bacteria.
Klebsiella pneumoniae exhibits high resistance levels to most 
antibiotics used for treatment, in particular to 3rd GC. In 
our study, 43.8% were resistant to cefalotin, 43.8% to ce-
furoxime, 12.1% to cefoxitin and 41% to cefotaxim.
The ESBL-producing strains represent 26.2% of  the to-
tal of  studied Klebsiella pneumoniae. These strains are very 
well represented in both hospital and community settings 
(Table 4). The percentage of  ESBL-producing strains 
isolated from hospitalized patients is slightly higher than 
that of  strains from outpatients (Table 5).  Initially, ESBL 
enzymes were restricted to nosocomial strains, they are 
recognized as major causes of  nosocomial acquired in-
fections, but now this is no longer the case, ESBL has 
emerged in an alarming way in the community and poses 
a real public health problem15.
Table 5: Distribution of ESBL-producing strains between in-come and out-come patients 
 
  Number of strains % 
  Community strains 227 40,1 
Nosocomial strains 339 59,9 
Total 566 100,0 
  
The ESBL-producing strains are mostly located in urolo-
gy and nephrology departments. Intensive care units are 
also concerned followed by pediatric unit, post-surgery 
and general surgery department. The emergence of  ES-
BL-producing strains especially in these services is exac-
erbated by the increase of  risk factors in patients such 
as immunodepression, chronic disease (diabetes, hyper-
tension, heart disease, etc…), massive use of  antibiotics 




Figure 4: Distribution of ESBL producing strains between different wards in the university  
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Mecanisms of  resistance to cephalosporins
Resistance to cephalosporins can be caused by produc-
tion of  ESBL and also of  cephalosporinases. Enterobac-
teriaceae with AmpC β-lactamase are important causes of  
cephalosporin and cephamycin resistance 16. AmpC en-
zymes hydrolyze efficiently 3rd GC but it is not inhibited 
by clavulanic acid. In general class C β-lactamase consti-
tutes a group of  enzymes widely distributed in Entero-
bacteriaceae. The most clinically important acquired AmpC 
β-lactamases are CMY-2-like, ACC, and DHA types. 
The most prevalent mechanisms of  resistance to several 
families of  antibiotics especially cephalosporins among 
Gram-negative pathogens are represented by emergence 
of  broad-spectrum β-lactamases. They have the property 
of  being inhibited by clavulanic acid17.
ESBL producing organisms were first detected in Eu-
rope. First reports were from Germany and England18, 
and the vast majority of  reports were from France19,20. 
In Tunisia, ESBL producing Enterobacteriaceae have been 
described as being the most important pathogens those 
causes nosocomial infections since their discovery at the 
end of  the 80 years. The three major families are TEM, 
SHV and CTX-M, and are plasmid located. 
In 1983, SHV-2 was isolated in Germany in Klebsiella 
ozaenae which possessed a β-lactamase which efficiently 
hydrolyzed cefotaxim and to a lesser ceftazidime21. In 
Tunisia, SHV-2 enzyme was the first ESBL described in 
1984 in pediatric ward at the Charles Nicolle Hospital in 
K.pneumoniae strains19. Between 1984 and 1988, TEM en-
zymes were reported. Since, the frequency of  3rd GC-re-
sistant Enterobacteriaceae has increased significantly22. 
This enzyme is able to hydrolyze ampicillin at a greater 
rate than carbenicillin, oxacillin, or cephalotin, and has 
negligible activity against extended spectrum cephalospo-
rins; it is inhibited by clavulanic acid. This enzyme largely 
dissimulated and replaced, the situation may have now 
turned out into a dominant CTX-M which hername re-
flects the potent hydrolytic activity against cefotaxim13, 
especially CTX-M-15 which emerged in an epidemic way. 
This enzyme has been described in the first time at the 
Charles Nicolle Hospital in Tunis in 2006. Since, it has 
been described several times in different hospitals and in 
different regions of  the country23,24, for example, in Mah-
dia which a city located near to Sousse, CTX-M-15 was the 
ESBL the most isolated 15. In our hospital CTX-M-15 
has been described in relation to NDM-1-producing mul-
tidrug-resistant strains24.
b- Resistance to carbapenem 
Treatment options for bacterial infections have gradually 
reduced in front of  increasing prevalence of  antibiotic 
resistance and the lack of  new antibiotic drug develop-
ment3,25. Carbapenems such as imipenem and ertapenem 
are antibiotics used as first line for the treatment of  severe 
infections caused by multi-resistant Enterobacteriaceae, such 
as Klebsiella pneumonia26. Carbapenemases are enzymes 
which are capable of  breaking down most β-lactams in-
cluding carbapenems, and thus conferring resistance to 
these drugs. Carbapenemase resistant Enterobacteriaceae 
have increasingly been reported worldwide in an alarming 
way in particular in Klebsiella pneumoniae27,28.
In our hospital, resistance to carbapenem molecules is 
mostly described in Klebsiella pneumoniae isolates. By intro-
ducing laboratory’s data of  resistance to ertapenem for 
the years 2010 and 2011, we have found that resistance to 
these molecules started from 2011 and has increased re-
markably from 2012. The distribution of  resistant strains 
between the hospital and the community shows that they 
are more isolated in the hospital (258/1250 and 84/910 
respectively), but their presence in the community pos-
es a real problem because we can no longer limit their 
emergence. It is difficult to modulate factors that enhance 
spread of  carbapenemase producers in the community, 
because, these factors are multiple and associated with 
lack of  hygiene, overuse of  antibacterial drugs and also 
increased worldwide travel28. 
The rate of  resistance to ertapenem has increased from 
2% in 2010 and 2011 to 17.7% in 2012. This rate de-
creased slightly in 2013 of  22% (0.21% in 2013 vs 0.26% 
in 2012) (Table*). This decrease is due to the rigorous 
application of  hygiene measures especially in the inten-
sive care units following training sessions for medical and 
paramedical personnel in order to limit their emergence. 
In 2014, the rate re-increases of  47% (0.33% in 2014 
vs 0.21% in 2013) (Table 6). Concerning imipenem, re-
sistance to this molecule increased from 0.38% in 2010 
to 1.3% in 2014. On the other hand, number of  strains 
showing an intermediate sensitivity to imipenem has in-
creased (11.6% in 2014) (Figure 5).
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Table 6: Percentage of resistance in klebsiella pneumoniae compared to the total 










 Years Total of admission in hospital 
wards 
Klebsiella pneumoniae 
resistant to ertapenem 
% of resistance 
2012 31506 83 0.26% 
2013 29629 64 0.21% 
2014 28428 94 0.33% 
 
 
Figure 5: Evolution of resistance to imipenem and ertapenem from 2010 to 2014 
Such as the results of  ESBL producing strains, bacteria 
with carbapenem resistance mechanism are mostly iso-
lated from samples coming from patient hospitalized in 
urology and intensive care unit departments, where there 
is a high flow of  admission of  patients who already have 
a favorable ground for the acquisition of  multidrug-resis-
tant bacterial infections. The rate of  resistant strains has 
increased in an alarming way in the nephrology depart-
ment in 2014.
-Phenotypic analysis of  carbapenem resistance 
mechanism
The results of  the Rosco discs realized on 241 Klebsiella 
pneumoniae resistant to ertapenem, which have been re-
covered from the laboratory preservation sack, allowed 
classifying strains into two major groups (Figure 6):
i- Klebsiella pneumoniae strains possessing an enzymatic 
mechanism of  carbapenem resistance by carbapenemas-
es production. This group is divided into two subgroups:
i-1- Metallo-β-lactamase producing strains: 17 strains 
showed increase in the diameter of  inhibition of  mero-
penem+dipicolinic acid disk compared with the disk of  
meropenem only. Those strains were characterized; they 
are NDM-1 producing strains24.
i-2- Oxacillinase-producing strains (OXA-48 like): 203 
strains showed resistance to temocillin indicating the 
presence of  class D carbapenemases.
In our hospital, class A carbapenemases especially KPC 
enzyme is not yet isolated.
ii- Strains possessing a non-enzymatic mechanism of  re-
sistance to carbapenems: 21 strains showed susceptibility 
to temocillin, a negative boronic acid and dipicolinic as-
says.
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In Sahloul hospital, carbapenem resistant Klebsiella pneu-
moniae was first described in 2008 in relation with overex-
pressing of  AmpC cephalosporinase CMY-4 combined 
with loss of  an outer membrane protein29. Since, no other 
cases have been described.
Our phenotypic study showed the dominance of  temo-
cillin-resistant Klebsiella pneumoniae, which is in favor of  
production of  class D carbapenemase (OXA-48 like). 
OXA-48 has the property to hydrolyze carbapenems but 
not third generation cephalosporins; its activity is not in-
hibited by clavulanic acid. It is often associated with oth-
er β-lactamases, particularly ESBL, which contributes to 
multiresistance of  strains30.
In Tunisia, the first report of  an OXA-48 producer was 
in 20105, since then, numerous cases have been described 
her emergence in an endemic way. The derivative OXA-
204 has also been described31,32. Eight variants of  OXA-
48 have been reported from different countries differing 
by few amino acid substitutions or deletions33,34: OXA-
162 35, OXA-18136, OXA-163, OXA- OXA-232 34, 
OXA-244, OXA-245 37, OXA-247 38 and OXA-405 39. 
OXA-48 is mainly present around Mediterranean coun-
tries; its worldwide distribution includes countries of  Eu-
rope especially France, Germany and Spain and countries 
of  North Africa such as Tunisia and Morocco. The Unit-
ed States and Canada have been spared from the produc-
tion of  this enzyme.
Other than class D carbapenemases, metallo-β-lactamas-
es have been also described in Tunisia. The first publica-
tion of  an MBL in an Enterobacteriaceae specie dates back 
to 2005 with a VIM-4-producing Klebsiella pneumoniae in 
Sfax40. In 2012, NDM-1 has been described for the first 
time in Tunisia41. In our hospital NDM-1 was the sub-
ject of  an emerging epidemic especially in intensive care 
unit24.
In the world, the most isolated carbapenemase is KPC; 
this plasmid resistance is increasingly described. Recently 
it has been detected in Tunisia but not yet in our hospi-
tal42,43.
Evolution of  resistance to colistin
Polymyxin antibiotics, including colistin, are one of  the 
few antibiotics still active on carbapenemase-producing 
Enterobacteriaceae. They are currently considered as last re-
sort antibiotics drugs for treating infections due to multi-
drug resistant Gram-negative pathogens. This is an anti-
biotic which cause cell membrane leakage. Unfortunately, 
resistance to this molecule has also been reported and still 
emerging worldwide. Mechanism of  resistance to colistin 
in Enterobacteriaceae can be due to modification of  lipid 
A with 4-amino-4-deoxy-L-arabinose and phosphoe-
thanolamine which neutralizes the negative charge, or 
to acquisition of  plasmid mediating gene named mcr-1, 
which encoded a phosphoethanolamine transferase that 
modifies the lipopolysaccharide structure of  Gram-neg-
ative bacteria44. Colistin plasmid resistance (mcr-1 gene) 
in Enterobacteriaceae was first detected in China at the end 
of  2015. Its plasmid character allows it to be very easily 
transferable between bacteria44.
In our hospital, the introduction of  colistin in the treat-
ment of  severe infections due to carbapenem-resistant 
strains has led to the appearance among isolated Klebsiella 
pneumoniae of  resistance to colistin. Its frequency remains 
for the moment very limited. Nine strains only showed 
resistance to colistin during the three years of  study, sev-
en were observed in the urine samples; only one was iso-
lated in a blood culture and one from a catheter. 
In different countries of  the world, more and more pub-
lications have spoken on the emergence of  colistin re-
sistant Klebsiella pneumoniae strains. In Taiwan, 17% of  
carbapenem resistant Klebsiella pneumoniae are resistant to 
colistin45. A surveillance study in Italy also revealed that 
43% of  carbapenemase-producing K. pneumoniae isolates 
were resistant to colistin46.
The new emerging resistances lead to a real therapeutic 
impasse. The situation is really alarming and requires tak-
ing and application of  precautionary measures in order to 
limit the emergence of  these multidrug resistant bacteria.
Conclusion
Our work showed the different profiles of  antibiotic re-
sistance in Klebsiella pneumoniae isolated at Sahloul hospital. 
The various mechanisms responsible for carbapenem re-
sistance have also been demonstrated. The emergence of  
new resistances can lead to a therapeutic impasse with se-
rious consequences on the health of  infected patients or 
even the increase in mortality rates. It is therefore import-
ant to insist on compliance with hospital hygiene rules 
and the rational use of  carbapenem to limit the spread 
of  such enzymes. The development of  other antibiotics 
molecules is therefore imperative to deal with infections 
caused by multiresistant bacteria.
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